ICON

ICLR · NASDAQ

$174.19+$6.05 (+3.60%)TodayMarket closed ·
Prev close $168.14

Latest news

  • Press releaseBusiness Wire

    ICON Schedules Third Quarter 2026 Earnings Conference Call

  • Press releaseBusiness Wire

    ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability

  • Press releaseBusiness Wire

    ICON Announces Pricing of USD 2.15 Billion Notes

  • Press releaseBusiness Wire

    ICON Announces Private Offering of Notes

  • Press releaseBusiness Wire

    ICON Announces Results of Annual General Meeting

  • Press releaseBusiness Wire

    ICON Reports Second Quarter 2026 Results

  • Press releaseBusiness Wire

    ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

  • Press releaseBusiness Wire

    ICON Schedules Second Quarter 2026 Earnings Conference Call

  • Press releaseGlobe Newswire

    INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in ICON plc (ICLR) to Contact Law Firm

  • News

    Icon Reports Q1 2026 Results: Full Earnings Call Transcript

  • News

    Icon Q1 Adj. EPS $2.50 Beats $2.42 Estimate, Sales $2.034B Beat $1.999B Estimate

  • Press releaseBusiness Wire

    ICON Reports First Quarter 2026 Results

  • News

    Earnings Scheduled For June 23, 2026

  • NewsPiero Cingari

    Earnings Volatility Watch: Micron And 9 Stocks Set For Big Moves This Week

  • News

    ICON Picks Microsoft to Expand AI Use in Clinical Trials

  • Press releaseBusiness Wire

    ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development

  • Press releaseBusiness Wire

    ICON Schedules First Quarter 2026 Earnings Conference Call

  • News

    Full Transcript: Icon Q4 2025 Earnings Call

  • Press releaseBusiness Wire

    ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation

  • Press releaseBusiness Wire

    ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq

  • Press releaseBusiness Wire

    ICON expands US early phase research capabilities with new clinic and outpatient centres

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseBusiness Wire

    ICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial Results

  • Press releaseBusiness Wire

    ICON and Advarra Introduce New 'Research-Ready,' Connected Site Network Model

  • Press releaseGlobe Newswire

    Lowey Dannenberg, P.C. is Investigating ICON PLC (NASDAQ: ICLR) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICON plc - ICLR

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ICON plc – ICLR

  • Press releaseBusiness Wire

    ICLR INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving ICON Public Limited Company

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICON plc - ICLR

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICON plc - ICLR

  • Press releaseGlobe Newswire

    ICLR SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

  • Press releaseBusiness Wire

    ICLR Investors Have Opportunity to Join ICON Public Limited Company Fraud Investigation with the Schall Law Firm

  • NewsVandana Singh

    FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer

  • NewsAvi Kapoor

    S&P 500 Falls Over 1%; American Electric Power Shares Gain After Upbeat Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.